In a mouse model of IPF triggered by BLM, RAP effectively deregulates molecules involved in fibrosis including hydroxyproline, TGF-β, α-SMA, suggesting that RAP has the potential to treat IPF (Piao et al. 2022). The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.